(TSX-V:DEX), VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) — Almadex Minerals Ltd. (“Almadex” or the “Company”) (TSX-V: “DEX”) is pleased to provide an update from its scout drilling program at the Paradise Project Nevada as well as its current drilling plans for the remainder of 2025. Results from the third hole of the Paradise […]
(TSX:EDT), PMA submission targeted for Q1 2026 following positive Tigris results and ongoing FDA interactions Company to host Corporate Update call on Wednesday, December 10, 2025 TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today
(CNSX:TCEC.CN),(OTC US:TCEFF),(Other OTC:TCEFF),(Boerse Frankfurt – Freiverkehr:9O0.F),(Boerse Frankfurt – Freiverkehr:C9O0.F), Vancouver B.C., Nov. 07, 2025 (GLOBE NEWSWIRE) — TERRA CLEAN ENERGY CORP. (“Terra” or the “Company“) (CSE: TCEC, OTCQB: TCEFF, FSE: C9O0) is pleased to announce that it has scheduled its annual general meeting of shareholders for December 8, 2025 (the “Meeting“). At that Meeting, amongst
(NASDAQ:ABEO), CLEVELAND, Nov. 07, 2025 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, November 12, 2025 at 8:30 a.m. ET to discuss its third quarter 2025 financial results and corporate progress. The conference call will be available via phone and webcast. To access the call,
(NASDAQ:CNTX), PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today shared two posters discussing the Company's CT-95 and CT-202 programs at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, being held
(TSX:TSL), VANCOUVER, British Columbia , Nov. 07, 2025 (GLOBE NEWSWIRE) — Tree Island Steel Ltd. (the “Company” or “Tree Island Steel“) (TSX:TSL) announced today that it has received approval from the Toronto Stock Exchange (the “TSX“) to renew its proposed normal course issuer bid to purchase up to 1,290,000 common shares, representing approximately 5% of
(TSX:BCT),(NASDAQ:BCTX),(NASDAQ:BCTXW),(NASDAQ:BCTXZ), Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses Increased tumor cell cytotoxicity induced by both Bria-BRES+(TM) (breast cancer) and Bria-PROS+(TM) (prostate cancer) Preclinical data reinforces broad potential of Bria-OTS+ platform across multiple indications PHILADELPHIA and VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE)
(NYSE:HLLY), THIRD CONSECUTIVE QUARTER OF CORE NET BUSINESS GROWTH LEVERAGE NOW BELOW 4X, THE LOWEST LEVEL SINCE 2022 Our strategic framework is fueling sustained momentum, with strong operational and financial results capped by our third consecutive quarter of core business growth. BOWLING GREEN, Ky., Nov. 07, 2025 (GLOBE NEWSWIRE) — Holley Performance Brands (NYSE: HLLY),
(NASDAQ:KURA), SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on November 3, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards
(NASDAQ:RLMD), CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial